You are here: Industry Insights > Market News > Roche's MabThera garners EU clearance as first biologic therapy for pemphigus vulgaris

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Roche's MabThera garners EU clearance as first biologic therapy for pemphigus vulgaris

firstwordpharmaMarch 15, 2019

Tag: Roche , mabthera , pemphigus vulgaris

Favorites

Roche announced Friday that regulators in Europe approved MabThera (rituximab) for the treatment of adults with moderate-to-severe pemphigus vulgaris (PV). The company noted that the drug "is the first biologic therapy approved by the European Commission for PV and the first major advancement in the treatment of the disease in more than 60 years."

The FDA approved MabThera in June last year for the treatment of patients with PV.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction

Next:Bristol-Myers Squibb denies defensive strategy

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Roche's MabThera garners EU clearance as first biologic therapy for pemphigus vulgaris | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Chromium-free Electrochemical Polishing Reagent for Stellite Alloy

PLR-DPEC100 DifferentialPhtoelectrochemical Reaction Device

Electrochemical Polishing Reagent for Titanium Alloy

Chromium-free Electrochemical Polishing Reagent for Stainless Iron

Emamectin benzoate agrochemical vacuum belt dryer manufacturer

Standard Type of Electrochemical Polishing Equipment

Electrochemical-Mechanical Abrasive Polishing Equipment

Specialty & agrochemical, pharma, Fertilizers and Biological Vacuum Belt Dryer Machine

Electrochemical Polishing Equipment of Scroll Mode

Electrochemical Processing Machine Of Inner Tube

Roche's MabThera garners EU clearance as first biologic therapy for pemphigus vulgaris

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>